MARKET

VKTXW

VIKING THERAPEUT
VKTXW
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-8.4559
-
1.378
-
Viking Therapeutics Showcases Advancements in Obesity and Metabolic Disease Drug Pipeline
Reuters · 12/09 00:40
BUZZ-Structure Therapeutics up after weight-loss drug succeeds mid-stage trial
Reuters · 12/08 13:49
BUZZ-Structure Therapeutics down ahead of weight-loss drug data 
Reuters · 12/08 11:51
Viking Therapeutics to Join Piper Sandler Healthcare Conference
Reuters · 11/25 21:05
Viking Therapeutics Showcases Pipeline Advances in Obesity and Metabolic Disease Programs
Reuters · 11/19 18:15
Viking Therapeutics Completes Enrollment in Phase 3 Obesity Drug Trial
Reuters · 11/19 07:55
VIKING THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 3 VANQUISH-1 TRIAL OF VK2735
Reuters · 11/19 07:55
VIKING THERAPEUTICS HIGHLIGHTS CLINICAL DATA FROM VK2735 OBESITY PROGRAM IN PRESENTATION AT OBESITYWEEK® 2025
Reuters · 11/06 12:05
More

Webull offers VIKING THERAPEUT stock information, including NASDAQ: VKTXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTXW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTXW stock methods without spending real money on the virtual paper trading platform.